- Home
- CNSP vs CERO Comparison
CNSP vs CERO Comparison
Compare CNSP & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- CERO
- Stock Information
- Founded
- CNSP 2017
- CERO 2017
- Country
- CNSP United States
- CERO United States
- Employees
- CNSP N/A
- CERO 8
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- CNSP Health Care
- CERO
- Exchange
- CNSP Nasdaq
- CERO Nasdaq
- Market Cap
- CNSP 4.0M
- CERO 3.6M
- IPO Year
- CNSP 2019
- CERO N/A
- Fundamental
- Price
- CNSP $8.39
- CERO $2.00
- Analyst Decision
- CNSP Strong Buy
- CERO Strong Buy
- Analyst Count
- CNSP 1
- CERO 2
- Target Price
- CNSP $20.00
- CERO $45.00
- AVG Volume (30 Days)
- CNSP 25.2K
- CERO 420.5K
- Earning Date
- CNSP 11-14-2025
- CERO 11-18-2025
- Dividend Yield
- CNSP N/A
- CERO N/A
- EPS Growth
- CNSP N/A
- CERO N/A
- EPS
- CNSP N/A
- CERO N/A
- Revenue
- CNSP N/A
- CERO N/A
- Revenue This Year
- CNSP N/A
- CERO N/A
- Revenue Next Year
- CNSP N/A
- CERO N/A
- P/E Ratio
- CNSP N/A
- CERO N/A
- Revenue Growth
- CNSP N/A
- CERO N/A
- 52 Week Low
- CNSP $4.93
- CERO $1.84
- 52 Week High
- CNSP $114.00
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- CNSP 44.14
- CERO 21.48
- Support Level
- CNSP $8.09
- CERO $1.84
- Resistance Level
- CNSP $9.30
- CERO $2.58
- Average True Range (ATR)
- CNSP 0.55
- CERO 0.42
- MACD
- CNSP -0.27
- CERO -0.08
- Stochastic Oscillator
- CNSP 5.95
- CERO 2.62
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.